Vemurafenib, another <i>BRAF</i> inhibitor, can reverse the resistance that develops with the <i>BRAF<sup>S365L</sup></i> mutation following dabrafenib combined with trametentinib treatment in melanoma, but none has been reported in NSCLC. This evidence concerns the gene BRAF and non-small cell lung carcinoma.